Michelle Hurst Joins Meridian Clinical Research as Director of Operational Project Management

Meridian Clinical Research, a leading multi-specialty site network, has hired Michelle Hurst as Director of Operational Project Management. In her role, Hurst will focus on optimizing performance and operational continuity across Meridian’s 23 sites. Before joining Meridian, Hurst was Director of Clinical Research at McKesson’s Intrafusion Research Network. At Intrafusion, Hurst developed and directed the company’s multi-specialty clinical research management program for more than 40 sites, including neurology, rheumatology, ophthalmology, and dermatology practices. “I am honored to join Meridian, a team that maintains the highest standards of quality … Read more

A Year-End Letter to Meridian Clients and Partners

On behalf of the Meridian team, we want to wish you and your family a safe and happy holiday season. We also want to thank you for an incredible year. 2020 began with great uncertainty. It ends with greater optimism. All at once, COVID-19 disrupted many ongoing trials while also thrusting clinical research and vaccine development into the public spotlight. During an adverse time, Meridian was fortunate to work with companies that rose to confront unprecedented challenges. Long hours, late nights, and lost sleep made progress possible. Meridian’s sites, investigators, … Read more

Meridian Clinical Research Opens Dedicated Research Center in Sioux City, IA

Meridian Clinical Research, a leading multi-specialty investigative research network, has opened a dedicated research center at 4802 Sunnybrook Drive in Sioux City, IA. Since 2005, Meridian has conducted clinical trials at a site in Dakota Dunes, SD. All Dakota Dunes personnel and studies will be moved to the new site in Sioux City, where David Ensz, MD, will continue to serve as the principal investigator for clinical trials. The move is a result of continued growth for the company, which was founded in 1999 and now operates at … Read more

Meridian Finishes Enrolling Participants for Moderna’s mRNA-1273 Phase 3 COVID-19 Vaccine Clinical Trial

Meridian Clinical Research, a leading investigative research network, has finished enrolling participants into Moderna’s Phase 3 clinical trial for mRNA-1273, its COVID-19 vaccine candidate. Today, Moderna reached its goal of 30,000 participants for the Phase 3 clinical trial. Meridian conducted the study at eight of its sites, and enrolled more than 2,750 participants into the trial. “We’re beyond grateful to every COVID-19 vaccine trial participant,” said Nicole Osborn, Founder and CEO of Meridian. “Many who have joined COVID-19 vaccine studies at Meridian are new to clinical research, and … Read more

U.S. Department of Health and Human Services (HHS) Officials Meet With Meridian Leaders to Discuss COVID-19 Vaccine Clinical Trials and Patient Recruitment

Officials from the U.S. Department of Health and Human Services (HHS) visited with leaders from Meridian Clinical Research in Savannah, GA. Following a tour of Meridian’s internal medicine site in Savannah, the group held a roundtable to discuss Meridian’s patient recruitment efforts and the research the company has conducted for COVID-19 vaccine clinical trials. Attendees included: HHS Eric D. Hargan, Deputy Secretary Rear Admiral Erica G. Schwartz, MD, JD, MPH, Deputy Surgeon General Ken Callahan, Deputy Chief of Staff, Office of the Deputy Secretary Chris Kotwicki, Special Assistant, Office … Read more

Meridian Wins 2020 Vaccine Industry Excellence (ViE) Awards for Best Clinical Trial Site and Best Clinical Trial Network

Meridian Clinical Research, a leading investigative research network, won the 2020 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Site. Meridian is also the largest member of Platinum Research Network, which won the ViE award for Best Clinical Trial Network. “It’s incredible to earn these awards when vaccine trials are the industry’s priority and so visible in the public spotlight,” said Nicole Osborn, Meridian founder and CEO. “It reaffirms the quality of work our investigators and staff put forward every day, and the trust we’ve established with … Read more

Meridian Clinical Research Ranked on the 2020 Inc. 5000 List

Inc. magazine ranked Meridian Clinical Research as 2,938 on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. Headquartered in Omaha, NE, Meridian is a multi-specialty site network with 24 sites nationwide. “It’s an honor to be recognized,” said Nicole Osborn, Meridian founder and CEO. “Our goal has always been to grow sustainably by partnering with leading physicians to drive high quality research.” The company’s ranking reflects growth from 2016 to 2019, but Osborn said 2020 has been Meridian’s most remarkable year … Read more

Meridian Clinical Research Begins Recruiting Healthy Adults for COVID-19 Vaccine Clinical Trial

Meridian Clinical Research announced today it has begun recruiting healthy adults for a Phase 3 clinical research study to evaluate the safety and effectiveness of mRNA-1273, a vaccine candidate against COVID-19. Sponsored by Moderna, the COVE Study is recruiting healthy volunteers ages 18 or older in high-risk populations, including the elderly, racial and ethnic minorities at higher risk for COVID-19, and essential workers in close contact with potentially infected persons. The Phase 3 study will evaluate if mRNA-1273 boosts the immune system to produce enough antibodies against SARS-CoV-2, … Read more

Operation Warp Speed Leaders Visit Meridian Clinical Research Site in Savannah, Discuss COVID-19 Vaccine Research Progress

Leaders of the Operation Warp Speed (OWS) program visited Meridian Clinical Research’s internal medicine site in Savannah, GA. Visitors included Moncef Slaoui, chief advisor, and General Gustave F. Perna, chief operating officer, of OWS. In May, the federal government announced the OWS program to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. Paul Bradley, MD, principal investigator at Meridian, enrolled the first patient into a Phase III COVID-19 vaccine clinical trial at the Savannah site on Monday, July 27, 2020. Meridian is conducting Phase … Read more

Paul Bradley, MD, Enrolls First Participant in Moderna’s Phase III COVID-19 Vaccine Clinical Trial

The first participant in the Moderna Phase III COVID-19 vaccine trial was enrolled this morning by Dr. Paul Bradley, Principal Investigator at Meridian’s internal medicine site in Savannah, GA. Compliments to Moderna on this significant milestone for its mRNA vaccine candidate (mRNA-1273) against COVID-19. 📰 Full release: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-phase-3-cove-study-mrna-vaccine-against-covid